Literature DB >> 29864783

Development and Validation of a Practical Two-Step Prediction Model and Clinical Risk Score for Post-Thrombotic Syndrome.

Elham E Amin1,2, Sander M J van Kuijk2, Manuela A Joore2, Paolo Prandoni3, Hugo Ten Cate1,4, Arina J Ten Cate-Hoek1,4.   

Abstract

BACKGROUND: Post-thrombotic syndrome (PTS) is a common chronic consequence of deep vein thrombosis that affects the quality of life and is associated with substantial costs. In clinical practice, it is not possible to predict the individual patient risk. We develop and validate a practical two-step prediction tool for PTS in the acute and sub-acute phase of deep vein thrombosis.
METHODS: Multivariable regression modelling with data from two prospective cohorts in which 479 (derivation) and 1,107 (validation) consecutive patients with objectively confirmed deep vein thrombosis of the leg, from thrombosis outpatient clinic of Maastricht University Medical Centre, the Netherlands (derivation) and Padua University hospital in Italy (validation), were included. PTS was defined as a Villalta score of ≥ 5 at least 6 months after acute thrombosis.
RESULTS: Variables in the baseline model in the acute phase were: age, body mass index, sex, varicose veins, history of venous thrombosis, smoking status, provoked thrombosis and thrombus location. For the secondary model, the additional variable was residual vein obstruction. Optimism-corrected area under the receiver operating characteristic curves (AUCs) were 0.71 for the baseline model and 0.60 for the secondary model. Calibration plots showed well-calibrated predictions. External validation of the derived clinical risk scores was successful: AUC, 0.66 (95% confidence interval [CI], 0.63-0.70) and 0.64 (95% CI, 0.60-0.69).
CONCLUSION: Individual risk for PTS in the acute phase of deep vein thrombosis can be predicted based on readily accessible baseline clinical and demographic characteristics. The individual risk in the sub-acute phase can be predicted with limited additional clinical characteristics. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 29864783     DOI: 10.1055/s-0038-1655743

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  Thrombolytic therapy in acute venous thromboembolism.

Authors:  Thita Chiasakul; Kenneth A Bauer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  External validation of the SOX-PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis.

Authors:  Anat Rabinovich; Chu-Shu Gu; Suresh Vedantham; Clive Kearon; Samuel Z Goldhaber; Heather L Gornik; Susan R Kahn
Journal:  J Thromb Haemost       Date:  2020-04-09       Impact factor: 5.824

3.  A predictive model for postthrombotic syndrome in proximal deep vein thrombosis patients.

Authors:  Peng Qiu; Junchao Liu; Fuzhen Wan; Yuqian Chen; Kaichuang Ye; Jinbao Qin; Qun Huang; Xinwu Lu
Journal:  Ann Transl Med       Date:  2021-04

4.  A Prediction Model Based on Blood Biomarker for Mortality Risk in Patients with Acute Venous Thromboembolism.

Authors:  Jianjun Jiang; Junshuai Xue; Yang Liu
Journal:  J Inflamm Res       Date:  2022-08-18

5.  Machine learning-based prediction of the post-thrombotic syndrome: Model development and validation study.

Authors:  Tao Yu; Runnan Shen; Guochang You; Lin Lv; Shimao Kang; Xiaoyan Wang; Jiatang Xu; Dongxi Zhu; Zuqi Xia; Junmeng Zheng; Kai Huang
Journal:  Front Cardiovasc Med       Date:  2022-09-16

Review 6.  Prevention and Management of the Post-Thrombotic Syndrome.

Authors:  Ilia Makedonov; Susan R Kahn; Jean-Philippe Galanaud
Journal:  J Clin Med       Date:  2020-03-27       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.